Osteosarcoma Exosome Priming of Primary Human Lung Fibroblasts Induces an Immune Modulatory and Protumorigenic Phenotype
Palmer EP., Cronise KE., Haines LA., Das S., Offermann A., Easton CP.
Prospective Study with a reported sample of 4, published in Cancer Res Commun (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Cancer Res Commun (2025)
- Reported sample size
- 4
- Source database
- Europe PMC
- PMID
- 40099972
- PMCID
- PMC11987067
- DOI
- 10.1158/2767-9764.crc-24-0371
- Citations
- 3
Abstract (original English)
Abstract Osteosarcoma (OS) is the most common malignant bone cancer. Thirty to forty percent of all patients with OS develop tumor recurrence, almost exclusively in the form of lung metastasis, which is associated with a dismal 20% 5-year survival rate. Cancer-associated fibroblasts are a critical cell type within the lung tumor microenvironment that promote immune suppression, drug resistance, and tumor cell survival. Prior work shows tumor cells can co-opt fibroblasts to a protumorigenic phenotype via exosome-mediated intercellular communication. Currently, the mechanisms by which OS exosomes modulate resident lung fibroblast (LF) function have not been evaluated. To investigate this, we isolated exosomes from a panel of six OS cell lines. We assessed the uptake and response of human donor–derived primary LFs (n = 4) to OS exosome treatment in vitro via flow cytometry, confocal fluorescent microscopy, proliferation assays, phosphokinase array, multiplex cytokine analysis, and RNA sequencing. We observed that LFs efficiently take up OS exosomes, which are associated with the induction of MAPK pathway activation, fibroblast proliferation, and significantly enhanced secretion of IL-6, CXCL8, and CCL2 compared with untreated LFs. RNA sequencing of exosome-treated LFs confirmed these responses and revealed significant enrichment of pathways related to cytokine secretion, prolifera
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.